anonymous
Guest
anonymous
Guest
Salix is dead. The B&L people told us exactly how this would go nine years ago when Valeant bought us. Single digit growth. Drug prices shooting through the roof. Leadership all eliminated and replaced with Valeant turds. No new investment in research or new products. Just keep squeezing existing brands and raising prices. It was always going to be like this. And now a significant generic challenge to X550. Does anyone think this ends well for us?
I hate to tell you, but there is no longer a "signficant" generic challenge to X550. There likely wont be any generics availablw until close to 2029.